|Last Update: 05/23/13 - 4:00 PM EDT|
|YTD Performance: 28.17%|
|Previous Close: $33.62|
|52 Week Range: $25.01 - $38.32|
|Oustanding Shares: 112,240,884|
|Market Cap: 3,773,538,520|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||12||11||14||13|
|Growth Rate (Year over Year)||-8.20%||-16.05%||-14.06%||-15.79%|
ENDP estimates were reduced after the FDA denied Opana CP, said UBS. Price target goes to $39.
ENDP was downgraded from Neutral to Sell, Lazard Capital Markets said. $27 price target. FDA denied Opana CP.
ENDP was downgraded from Neutral to Underweight, Piper Jaffray said. $22 price target. Outlook for generic competition remains uncertain.
Shares of ENDP downgraded to Perform from Outperform, Oppenheimer said. Valuation call.
Shares of ENDP now seen reaching $40, UBS said. Estimates also lowered on 2013 guidance. Buy rating.
Shares of ENDP now seen reaching $32, Oppenheimer said. Estimates also lowered generic competition. Outperform rating.
ENDP was downgraded from Overweight to Neutral, Piper Jaffray said. Opana ER is facing generic competition. $28 price target.
ENDP was downgraded from Hold to Underperform, Needham said. Core franchises will likely continue to deteriorate.
Shares of ENDP now seen reaching $45, UBS said. Estimates also lowered following investor day. Buy rating.
ENDP was placed on the US 1 list, Bank of America/Merrill Lynch said. Opana ER market share should soon recover. Buy rating and $40 price target.